Opening the Door to Discovery: How CJD Patients and Families Can Engage With Clinical Research

When a family receives a CJD diagnosis, the question that follows almost immediately is: Is there anything being done? The answer — though rarely delivered with sufficient clarity — is yes. Researchers across the United States and internationally are actively working to understand prion diseases at the molecular level, to identify compounds that may slow or interrupt disease progression, and to develop diagnostic tools that can detect CJD earlier and more reliably than ever before.

Clinical trials are the mechanism through which that laboratory work becomes medicine. They are also, for many CJD patients and families, an underutilized opportunity — not because families lack interest, but because the pathway into clinical research is rarely explained in plain terms by the clinicians managing day-to-day care.

This article is intended to change that.

What a Clinical Trial Actually Is

A clinical trial is a structured scientific study conducted in human participants to evaluate the safety, efficacy, or mechanism of a medical intervention — which might be a drug, a diagnostic procedure, a device, or even a behavioral protocol. Trials are organized into phases, each with a distinct purpose.

Phase I trials focus primarily on safety. They typically involve small numbers of participants and are designed to determine how the body responds to a new treatment, identify safe dosage ranges, and document side effects. Phase II trials expand the participant pool and begin to assess whether the intervention shows preliminary evidence of effectiveness. Phase III trials involve larger, often randomized groups and are designed to generate the evidence required for regulatory approval by the FDA. Phase IV studies occur after a treatment has been approved and continue to monitor long-term outcomes in broader populations.

For rare diseases like CJD, the trial landscape looks somewhat different than it does for more common conditions. Enrollment numbers are smaller, trials may be conducted at only a handful of specialized centers nationwide, and the pace of research is shaped by the relative scarcity of research funding compared to more prevalent diseases. These realities make it all the more important for families to be proactive about identifying and evaluating available opportunities.

Why Participation Matters Beyond the Individual

For some families, the decision to pursue clinical trial enrollment is motivated entirely by the hope that a study treatment might benefit their loved one directly. That hope is understandable and legitimate. But it is worth acknowledging another dimension of participation that many families find deeply meaningful: the contribution to science itself.

Because CJD is rare, every patient who enrolls in a study, contributes biological samples, or participates in a natural history registry adds information that researchers cannot obtain any other way. The data gathered from a single well-documented patient can meaningfully advance the field's understanding of disease mechanisms, biomarker reliability, or treatment response. Families who have walked this road often describe their decision to participate in research as one of the most purposeful choices they made during an otherwise powerless time.

At the Newark CJD Center, we have seen this firsthand. Families who engage with the research community — even when direct therapeutic benefit is uncertain — consistently report a greater sense of agency and connection to something larger than their individual circumstances.

How to Find and Evaluate CJD Clinical Trials

The primary public database for clinical trials conducted in the United States is ClinicalTrials.gov, maintained by the National Institutes of Health. Searching for "prion disease," "Creutzfeldt-Jakob," or "CJD" will return a list of currently recruiting, active, and completed studies. Each listing includes the study's purpose, eligibility criteria, participating sites, contact information, and current status.

When evaluating a trial, families should ask the following questions:

• What is the study testing, and what is the scientific rationale? Understanding the mechanism behind a proposed intervention — even at a basic level — helps families assess whether the study is grounded in credible science.
• What are the eligibility criteria? Many trials have specific requirements related to disease subtype, stage of progression, age, or prior treatments. Confirming eligibility before investing significant time and energy is essential.
• What does participation involve? Some trials require regular in-person visits to a study site; others may allow remote data collection or biospecimen submission by mail. Understanding the practical burden of participation helps families make realistic decisions.
• What are the known and potential risks? All clinical trials carry some degree of risk. The informed consent process is designed to ensure participants understand those risks fully before enrolling. Do not hesitate to ask the research team for clarification on any point.
• Is there a placebo arm? In randomized controlled trials, some participants receive a placebo rather than the active intervention. Understanding this possibility is important for managing expectations.
• What compensation or support is available? Many trials cover the cost of study-related procedures and may provide travel reimbursement. Some offer access to investigational treatments at no cost.

Beyond ClinicalTrials.gov, the CJD Foundation maintains a research directory and can connect families with patient advocacy networks that track emerging study opportunities. The National Prion Disease Pathology Surveillance Center at Case Western Reserve University operates a national surveillance program and biobank that accepts tissue and fluid donations, contributing directly to ongoing research.

The Role of Compassionate Use and Expanded Access

For patients who do not qualify for a clinical trial — or for whom no suitable trial is currently recruiting — the FDA's Expanded Access program (sometimes called "compassionate use") may offer another pathway. This program allows patients with serious or life-threatening conditions to access investigational treatments outside of a clinical trial, under specific circumstances and with physician oversight.

Expanded access is not universally available, and it is not a guarantee of benefit. However, for families who have exhausted standard diagnostic and treatment pathways, it represents a legitimate avenue worth discussing with a neurologist experienced in prion diseases. The FDA's website provides detailed guidance on how to request expanded access, and the Newark CJD Center can help families understand whether this option may be appropriate in their specific situation.

How the Newark CJD Center Supports Research Engagement

Navigating the clinical research landscape is not something families should have to do alone, particularly during a time of acute medical and emotional crisis. The Newark CJD Center serves as a resource hub for families seeking to understand their research options — helping to identify relevant trials, interpret eligibility requirements, coordinate with research teams at other institutions, and connect patients with the broader prion disease research community.

We also work to ensure that families who are not in a position to pursue active trial participation are still given opportunities to contribute to science in other meaningful ways — including biospecimen donation, participation in natural history studies, and engagement with patient registries that inform future research design.

If you or a family member has received a CJD diagnosis and you want to understand what research opportunities may be available, we encourage you to reach out to our team directly. The science of prion disease is advancing. The families we serve are part of that advancement.